Patel Yogin, Shah Nirav, Lee Ji Shin, Markoutsa Eleni, Jie Chunfa, Liu Shou, Botbyl Rachel, Reisman David, Xu Peisheng, Chen Hexin
Department of Biological Science, University of South Carolina, Columbia, SC, USA.
Center for Colon Cancer Research, University of South Carolina, Columbia, SC, USA.
Oncotarget. 2016 Apr 5;7(14):18295-308. doi: 10.18632/oncotarget.7577.
Human epidermal growth factor receptor 2 (HER2 or ErBb2) is a receptor tyrosine kinase overexpressed in 20-30% of breast cancers and associated with poor prognosis and outcome. Dysregulation of several microRNAs (miRNAs) plays a key role in breast cancer progression and metastasis. In this study, we screened and identified miRNAs dysregualted in HER2-positive breast cancer cells. Our molecular study demonstrated that miR-489 was specifically downregulated by the HER2-downstream signaling, especially through the MAPK pathway. Restoration or overexpression of miR-489 in HER2-positive breast cancer cells significantly inhibited cell growth in vitro and decreased the tumorigenecity and tumor growth in xenograft mice. Mechanistically, we found that overexpression of miR-489 led to the decreased levels of HER2 and SHP2 and thus attenuated HER2-downstream signaling. Furthermore, we for the first time demonstrated that HER2 is a direct target of miR-489 and therefore HER2-SHP2-MAPK and miR-489 signaling pathways form a mutually inhibitory loop. Using quantitative real-time PCR analysis and Fluorescent in situ hybridization technique (FISH), we found that miR-489 was expressed at significantly lower level in tumor tissues compared to the adjacent normal tissues. Downregulation of miR-489 in breast cancers was associated with aggressive tumor phenotypes. Overall, our results define a double-negative feedback loop involving miR-489 and the HER2-SHP2-MAPK signaling axis that can regulate breast cancer cell proliferation and tumor progression and might have therapeutic relevance for HER2-positive breast cancer.
人表皮生长因子受体2(HER2或ErBb2)是一种受体酪氨酸激酶,在20%-30%的乳腺癌中过表达,与不良预后和结局相关。几种微小RNA(miRNA)的失调在乳腺癌进展和转移中起关键作用。在本研究中,我们筛选并鉴定了HER2阳性乳腺癌细胞中失调的miRNA。我们的分子研究表明,miR-489被HER2下游信号特异性下调,尤其是通过丝裂原活化蛋白激酶(MAPK)途径。在HER2阳性乳腺癌细胞中恢复或过表达miR-489可显著抑制体外细胞生长,并降低异种移植小鼠的致瘤性和肿瘤生长。机制上,我们发现miR-489过表达导致HER2和SHP2水平降低,从而减弱HER2下游信号。此外,我们首次证明HER2是miR-489的直接靶点,因此HER2-SHP2-MAPK和miR-489信号通路形成相互抑制环。使用定量实时聚合酶链反应分析和荧光原位杂交技术(FISH),我们发现与相邻正常组织相比,miR-489在肿瘤组织中的表达水平显著降低。乳腺癌中miR-489的下调与侵袭性肿瘤表型相关。总体而言,我们的结果定义了一个涉及miR-489和HER2-SHP2-MAPK信号轴的双负反馈环,该环可调节乳腺癌细胞增殖和肿瘤进展,可能对HER2阳性乳腺癌具有治疗意义。